Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Cross-sectional Study to Assess the Effectiveness and Safety of Ofatumumab (Kesimpta®) in Patients With Relapsing Multiple Sclerosis in the Spanish Clinical Practice

Recruiting

Conditions: Relapsing Forms of Multiple Sclerosis

Interventions: Other: ofatumumab

First Posted Date: 2024-02-09

Last Posted Date: 2024-08-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 310

Registration Number: NCT06251986

Locations: 🇪🇸
Novartis Investigative Site, Zaragoza, Spain

Real-World Patient Characteristics, Treatment Patterns, and Clinical Outcomes Among Patients With BRAF-Positive Metastatic Melanoma

Completed

Conditions: BRAF-positive Metastatic Melanoma

First Posted Date: 2024-02-09

Last Posted Date: 2024-02-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 785

Registration Number: NCT06251934

Locations: 🇺🇸
Novartis, East Hanover, New Jersey, United States

A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.

Phase 1

Recruiting

Conditions: Breast Cancer

Interventions: Drug: [68Ga]Ga-NeoB
Drug: [177Lu]Lu-NeoB
Drug: Capecitabine

First Posted Date: 2024-02-08

Last Posted Date: 2024-11-25

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 58

Registration Number: NCT06247995

Locations: 🇪🇸
Novartis Investigative Site, Barcelona, Catalunya, Spain

A Prospective, Open-label Study of [68Ga]Ga-DOTA-TATE in Patients With Neuroendocrine Neoplasms (NENs) and Healthy Volunteers in Japan

Phase 3

Recruiting

Conditions: Neuroendocrine Neoplasms

Interventions: Drug: [68Ga]Ga-DOTA-TATE
Drug: 68Ge/68Ga Generator

First Posted Date: 2024-02-05

Last Posted Date: 2024-11-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 70

Registration Number: NCT06240741

Locations: 🇯🇵
Novartis Investigative Site, Kyoto, Japan

Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy

Phase 3

Recruiting

Conditions: Hypertension

Interventions: Drug: LCZ/AML 200 mg/2.5 mg
Drug: LCZ/AML 200 mg/5 mg
Drug: LCZ/AML 200 mg/10 mg
Drug: LCZ

First Posted Date: 2024-02-01

Last Posted Date: 2024-07-15

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 688

Registration Number: NCT06236061

Locations: 🇯🇵
Novartis Investigative Site, Osaka, Japan

Migraine Survey in Gulf Region

Recruiting

Conditions: Migraine

Interventions: Other: erenumab

First Posted Date: 2024-02-01

Last Posted Date: 2024-07-31

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 200

Registration Number: NCT06237062

Locations: 🇦🇪
Novartis Investigative Site, Ras Al Khaimah, United Arab Emirates

Survey to Assess Physicians' Knowledge of Exjade Posology and Biological Monitoring Recommendations as Described in the Educational Materials

Completed

Conditions: Chronic Iron Overload

Interventions: Other: Physician survey

First Posted Date: 2024-01-22

Last Posted Date: 2024-05-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 400

Registration Number: NCT06215287

Locations: 🇨🇭
Novartis Investigative Site, Basel, Switzerland

Real-world Effectiveness of Asciminib and Treatment Patterns in Patients With Chronic Myeloid Leukemia With T315I Mutation - a Chart Review Study of Patients Treated in the Asciminib Managed Access Program (MAP)

Completed

Conditions: Chronic Myeloid Leukemia With T315I Mutation

First Posted Date: 2024-01-18

Last Posted Date: 2024-01-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 31

Registration Number: NCT06211153

Locations: 🇨🇭
Novartis, Basel, Switzerland

Real-world Evaluation of BEOVU (Brolucizumab) Effectiveness and Durability for Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD)

Completed

Conditions: Neovascular (Wet) Age-related Macular Degeneration

First Posted Date: 2023-12-28

Last Posted Date: 2023-12-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 2079

Registration Number: NCT06184360

Locations: 🇺🇸
Novartis, East Hanover, New Jersey, United States

Injection Intervals in Real-world Neovascular Age-related Macular Degeneration (nAMD) Patients Switching to Brolucizumab With at Least 12 Months of Follow-up

Completed

Conditions: Neovascular Age-related Macular Degeneration

First Posted Date: 2023-12-21

Last Posted Date: 2023-12-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 414

Registration Number: NCT06178770

Locations: 🇺🇸
Novartis, East Hanover, New Jersey, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy